{"id":264341,"date":"2026-02-02T20:01:08","date_gmt":"2026-02-02T20:01:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/nz\/264341\/"},"modified":"2026-02-02T20:01:08","modified_gmt":"2026-02-02T20:01:08","slug":"pharmac-makes-move-towards-funding-weight-loss-drug-wegovy","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/nz\/264341\/","title":{"rendered":"Pharmac makes move towards funding weight loss drug Wegovy"},"content":{"rendered":"<p><img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.newsbeep.com\/nz\/wp-content\/uploads\/2026\/02\/4K501Y2_AFP__20240712__dpa_pa_240712_99_710151_dpai__v1__HighRes__SlimmingSyringes_jpg.jpeg\" width=\"1050\" height=\"745\" alt=\"11 July 2024, Berlin: Wegovy\" brand=\"\" slimming=\"\" syringes=\"\" are=\"\" sold=\"\" in=\"\" the=\"\" achat=\"\" pharmacy=\"\" mitte.=\"\" photo:=\"\" jens=\"\" kalaene=\"\" by=\"\" dpa=\"\" picture-alliance=\"\" via=\"\" afp=\"\"\/><\/p>\n<p class=\"photo-captioned__information\">\nWegovy is a weight loss drug that is injected weekly.<br \/>\nPhoto: JENS KALAENE\n<\/p>\n<p>Pharmac has taken the first steps towards funding weight loss drug Wegovy after an advisory panel provisionally recommended funding it as a high priority for some people.<\/p>\n<p>Wegovy or semaglutide is a GLP-1 receptor agonist for weight loss.<\/p>\n<p>The drug first became available here in July last year, and currently <a href=\"https:\/\/www.rnz.co.nz\/news\/national\/578050\/wegovy-an-instant-hit-among-both-patients-and-doctors-but-with-a-warning\" rel=\"nofollow noopener\" target=\"_blank\">costs about $460 a month<\/a>.<\/p>\n<p>Pharmac Director of Advice and Assessment, David Hughes, said the Obesity Treatments Advisory Group have provisionally recommended it be funded for chronic weight management in people with a high Body Mass Index (BMI) and associated comorbidities.<\/p>\n<p>The recommendation is subject to Special Authority criteria, which will limit who can prescribe it.<\/p>\n<p>The recommendation has been announced after the <a href=\"https:\/\/www.rnz.co.nz\/news\/national\/584348\/funding-wegovy-will-save-taxpayer-money-in-long-run-specialist\" rel=\"nofollow noopener\" target=\"_blank\">advisory group met in December<\/a>, with a full record of the meeting expected to be available by March.<\/p>\n<p>A &#8216;goldrush&#8217; of weight loss drugs<\/p>\n<p>Boyd Swinburn, an Auckland University Professor of global health and nutrition, told Morning Report, the move towards funding came at a time when there was a &#8220;gold rush&#8221; on these kinds of drugs that were very effective at reducing obesity.<\/p>\n<p>&#8220;So the pressure is on to really deliver them,&#8221; he said, &#8220;the problem at the moment is the expense.&#8221;<\/p>\n<p>Wegovy helped reduce the incidents of diseases including type-two diabetes and sleep apnea, Swinburn said.<\/p>\n<p>The struggle for Pharmac would be finding a mechanism to make it affordable within its fixed budget, he said.<\/p>\n<p>&#8220;Type two diabetes is a very chronic, expensive disease so Pharmac would be interest in drugs that would reduce that by bringing it under control or even reversing it.&#8221;<\/p>\n<p>Weight loss specialist Dr Gerard McQuinlan, told Morning Report, there had been lots of good evidence that Wegovy slowed the rates of heart disease and strokes in patients.<\/p>\n<p>He said most of his patients who were on Wegovy had some sort of co-morbidity, rather than just being classed as obese.<\/p>\n<p>McQuinlan believed if the drug was funded, the advisory board would most likely be looking at making it available to high-risk patients.<\/p>\n<p>&#8220;There have been really good trials showing 20 percent reduction in heart disease patients getting a second event.&#8221;<\/p>\n<p>Having the drug unfunded created inequity, McQuinlan said, and if it was funded it would create clear criteria for managing patients with obesity and heart disease.<\/p>\n<p>&#8220;I think it will be targeted to certain high-risk patients. [It] will not be for mass-prescribing, probably for people who already have established cardiovascular disease.&#8221;<\/p>\n<p>Previously, Pharmac had received two applications to fund Wegovy.<\/p>\n<p>The first was in September, for people with an established cardiovascular disease (such as someone who has had a heart attack or stroke) and a Body Mass Index (BMI) of 27 or higher. The second was in October, for chronic weight management in people with a BMI of 30 or higher, with at least one weight-related comorbidity.<\/p>\n<p>New Zealand has the third-highest adult obesity rate in the Organisation for Economic Co-operation and Development (OECD).<\/p>\n<p><a href=\"https:\/\/radionz.us6.list-manage.com\/subscribe?u=211a938dcf3e634ba2427dde9&amp;id=b3d362e693\" rel=\"nofollow noopener\" target=\"_blank\">Sign up for Ng\u0101 Pitopito K\u014drero, a daily newsletter<\/a> curated by our editors and delivered straight to your inbox every weekday.<\/p>\n","protected":false},"excerpt":{"rendered":"Wegovy is a weight loss drug that is injected weekly. Photo: JENS KALAENE Pharmac has taken the first&hellip;\n","protected":false},"author":2,"featured_media":264342,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[48,47,134,524,111,43,139,69,49,46,44,45],"class_list":["post-264341","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-audio","tag-current-affairs","tag-health","tag-medication","tag-new-zealand","tag-news","tag-newzealand","tag-nz","tag-podcasts","tag-public-radio","tag-radio-new-zealand","tag-rnz"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/264341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=264341"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/264341\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/264342"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=264341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=264341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=264341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}